Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126976071 | 12697607 | 1 | I | 201606 | 20160628 | 20160830 | 20160830 | PER | US-MYLANLABS-2016M1027261 | MYLAN | 36.08 | YR | M | Y | 68.27000 | KG | 20160830 | PH | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126976071 | 12697607 | 1 | PS | ESOMEPRAZOLE MAGNESIUM D/R | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 40 MG, QD | 3045241 | 78936 | 40 | MG | CAPSULE | QD | |||||
| 126976071 | 12697607 | 2 | C | ZYRTEC | CETIRIZINE HYDROCHLORIDE | 1 | UNK, PRN | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126976071 | 12697607 | 1 | Gastrooesophageal reflux disease |
| 126976071 | 12697607 | 2 | Seasonal allergy |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126976071 | 12697607 | Drug effect decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126976071 | 12697607 | 1 | 2016 | 0 |